DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for eustachian tube disease — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEustachian tube disease maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for eustachian tube disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
proteasome 20S subunit beta 4 (PSMB4) — PSMB4 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet nendrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8BZL · 2.14 Å · ligand 1-ETHYL-PYRROLIDINE-2,5-DIONE (NEN). Experimental structure, not a prediction.
What the evidence adds up to
A 2021 systematic review and meta-analysis of medical management for eustachian tube dysfunction in adults found no level 1 evidence for any non-surgical treatment. Among nine pooled studies, 50.3% of patients (95% CI, 41.7–59.0) reported symptomatic improvement with medical management overall, but Eustachian Tube Dysfunction Questionnaire-7 scores improved by only −0.88 (95% CI, −1.12 to −0.64), a change the authors judged clinically non-significant. Intranasal corticosteroids were not efficacious, improving only 11% to 18% of chronic cases. Subacute symptoms improved in 30% to 64% of cases, chronic symptoms in 11% to 50%. Therapies such as Politzer devices and Valsalva manoeuvres produced minimally beneficial results. The review included only studies with level 2 or 3 evidence.
A 2013 review of treatment options states that balloon dilation or microdebrider eustachian tuboplasty are feasible for refractory dilatory dysfunction as an alternative to tympanostomy tube placement. For patulous eustachian tubes, insertion of a shim or fat graft reconstruction within the lumen of the orifice may be effective. The same review notes that continued basic science research into the cause of dysfunction, the mechanisms of benefit from intervention, and long-term clinical outcomes are necessary. A 2011 article tracing the evolution of eustachian tube surgery observes that attempts to address eustachian tube dysfunction surgically have spanned several centuries and have often fallen short of success, with occult anatomic position, unclear function, and misunderstood physiology likely contributing to the delayed development of effective interventions.
A 2022 letter responding to a 2015 consensus statement on definition, types, clinical presentation and diagnosis of eustachian tube dysfunction offers contributions to the discussion but provides no new trial data. The 2021 meta-analysis explicitly states that further randomised controlled trials are needed to discern efficacy of single-agent medical therapies. What remains missing are adequately powered, placebo-controlled trials that stratify patients by duration of symptoms (subacute versus chronic) and by underlying aetiology, as well as long-term outcome data for both medical and surgical interventions.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Archives of Otolaryngology - Head and Neck Surgery · 2011 · 117 citations
Management of Eustachian Tube Dysfunction With Nasal Steroid Spray
AbstractOBJECTIVE: To determine the efficacy of intranasal aqueous triamcinolone acetonide in treating the tympanometric signs and symptoms of eustachian tube dysfunction, such as otitis media with effusion and negative middle ear pressure. DESIGN: Randomized, placebo-controlled, double-blind prospective clinical trial. SETTING: Tertiary referral clinic. PATIENTS: Adults (≥18 years) and children (6-17 years) presenting with otitis media with effusion, negative middle ear pressure, or both. INTERVENTIONS: The 2 treatment arms consisted of aqueous triamcinolone or matching placebo administered once daily intranasally for 6 weeks. All subjects underwent tympanometry, otologic examination, and completion of a symptom questionnaire before and after treatment. MAIN OUTCOME MEASURES: Resolution of abnormal tympanometry and change in symptom scores (severity and frequency). RESULTS: Ninety-one patients presenting from September 1, 2005, through December 31, 2008, with otitis media with effusion or with negative middle ear pressure were enrolled and randomly assigned to treatment or placebo in a double-blind manner. No statistically significant difference in normalization of abnormal tympanometric signs was demonstrated with the active treatment arm compared with placebo on either a per-patient basis (19% vs 32%; P = .18) or a per-ear basis (22% vs 35%; P = .15). There was also no significant difference in the overall poststudy symptom score between the 2 treatment arms, after adjusting for the prestudy overall symptom score in an analysis of covariance model (P = .27). CONCLUSION: These findings do not support the use of intranasal steroid sprays to treat the manifestations of eustachian tube dysfunction. Trial Registration clinicaltrials.gov Identifier: NCT00279916.
Current Opinion in Otolaryngology & Head & Neck Surgery · 2013 · 104 citations
What is the full range of medical and surgical treatments available for patients with Eustachian tube dysfunction?
AbstractPURPOSE OF REVIEW: To present the current medical and surgical treatment options for Eustachian tube dysfunction. RECENT FINDINGS: Balloon dilation or microdebrider Eustachian tuboplasty are feasible treatment options for patients with refractory dilatory dysfunction as an alternative to tympanostomy tube placement. There is increasing evidence that repair of patulous Eustachian tubes by the insertion of a shim or fat graft reconstruction within the lumen of the Eustachian tube orifice may be effective. SUMMARY: In patients with Eustachian tube dysfunction that is refractory to medical management, newer surgical techniques may provide symptomatic relief with a reasonable duration. Continued basic science research into the cause of dysfunction, the mechanisms of benefit from intervention and long-term clinical outcomes are necessary.
AbstractEustachian tube dysfunction (ETD) is a common condition that lacks a widely accepted treatment. Attempts to address ETD surgically have spanned several centuries and have often fallen short of success. It is probable that occult anatomic position, unclear function, and misunderstood physiology have contributed to the delayed development of effective interventions for ETD. This article traces the evolution of therapeutic interventions of the Eustachian tube through the present day. Reasons for success and failure are highlighted, with implications for the future of Eustachian tube surgery.
The Laryngoscope · 2021 · 31 citations · open access
Medical Management for Eustachian Tube Dysfunction in Adults: A Systematic Review and <scp>Meta‐Analysis</scp>
AbstractOBJECTIVE: Medical treatment for eustachian tube dysfunction (ETD) is varied, with physician preference driving treatment choice and limited guidance for these options. An evaluation of the efficacy of medical management (MM) for ETD is warranted. METHODS: A systematic review of three databases (PubMed, Scopus, and Embase) was performed through December 2020. Adults treated nonsurgically for ETD were included. Exclusion criteria were as follows: patulous ETD, ETD deriving from craniofacial anomalies, or surgical treatment. Data were extracted independently by two reviewers according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A meta-analysis of continuous measures, proportions, and risk ratio was conducted. RESULTS: Twelve articles were identified by systematic review, with either level 2 or 3 evidence. A meta-analysis of available data was performed on nine studies. A pooled cohort found 50.3% (95% confidence interval [CI], 41.7-59.0) of patients experienced symptomatic improvement with MM. ETDQ-7 scores improved in a clinically nonsignificant manner by -0.88 (95% CI, -1.12 to -0.64) following medical treatment. Further, MM benefited from subacute and chronic symptoms in 30% to 64% and 11% to 50% of cases, respectively. Intranasal corticosteroids (INCS) were not efficacious, improving only 11% to 18% of chronic cases. Therapies such as Politzer devices and Valsalva therapy had minimally beneficial results. CONCLUSION: Our review did not find any level 1 evidence for MM of ETD in adults. Available evidence indicates INCS are ineffective for chronic symptoms and the efficacy of nonsurgical options for subacute ETD has yet to be determined. Further randomized controlled trials are needed to discern efficacy of single-agent medical therapies. Laryngoscope, 132:849-856, 2022.
International Journal of Health Sciences · 2022 · 0 citations · open access
Letter to colleagues in reference to: “Eustachian tube dysfunction: Consensus statement on definition, types, clinical presentation and diagnosis”
AbstractAfter reading the editorial comment article entitled, “Eustachian tube dysfunction: Consensus statement on definition, types, clinical presentation and diagnosis” published in Clinical Otolaryngology (2015; 40 (5): 407-411), I would like to congratulate the authors for their successful consensus, and I wish to make some contributions to the discussion.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
